EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)

A First‐In‐Human, Randomized, Placebo‐Controlled Single and Multiple Ascending Dose Study of Izicopan (INF904), A Second‐Generation Oral Small Molecule C5a Receptor Inhibitor, in Healthy Participants

Joseph F Grippo, Anja Pfaff, Zhongli Xu, Isabell Otto, Claus Thielert, Mihaly Imre, Rui Liu, Wantanee Phuapradit, Yazhong Pei, Cuie Chen, Maria Habel, Renfeng Guo und 1 weitere

Clinical Pharmacology in Drug Development · 2026-11 · 15 (11)

DOI: 10.1002/cpdd.70123 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 01.11.2026. Verfasst von Joseph F Grippo und 12 weiteren Autor:innen. Beteiligte Einrichtung: InflaRx GmbH, Jena, Germany. Hauptthemen laut MEDLINE: Receptor, Anaphylatoxin C5a. Die Arbeit nennt 13 Literaturangaben. Gefördert von: InflaRx.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This was a first‐in‐human, single‐center, Phase 1 study of izicopan (formerly INF904), a potent oral, second‐generation small molecule antagonist of C5aR1, in healthy adults. Participants were randomized to a single oral dose of izicopan 3–240 mg or matched placebo (single ascending dose [SAD]), or multiple doses of izicopan 30 mg once daily (QD), 30 or 90 mg twice daily (BID), or matched placebo, for 14 days (multiple ascending dose [MAD]). In the SAD study, izicopan plasma concentration increased with dose from 3 to 240 mg; the mean maximum plasma concentration (C max ) was 21.5–1216.0 ng/mL, reached at a median time (t max ) of 3.5–6.0 h, followed by a biphasic decline. In the MAD study, a steady state appeared to have been reached within 14 days, and AUC 0‐tau exhibited an accumulation ratio of ∼2‐fold following BID dosing, suggesting an effective half‐life of ∼12 h. In an ex vivo whole blood PD assay, izicopan resulted in >90% blockade of CD11b upregulation by recombinant human C5a across almost all dose cohorts from Days 2–15. Adverse events were mild or moderate in severity. In conclusion, izicopan was safe across all single and multiple doses evaluated. Sufficient izicopan exposure was achieved rapidly to exert >90% blockade of C5a‐C5aR1 signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Anaphylatoxin C5aHumansAdultMaleFemaleAdministration, OralDose-Response Relationship, DrugYoung AdultMiddle AgedHealthy VolunteersDouble-Blind MethodArea Under CurveAdolescentDrug Administration Schedule

Stichwörter der Autor:innen

C5a receptor inhibitorINF904Phase 1first‐in‐humanimmune‐inflammatory diseasesizicopan

Substanzen

Receptor, Anaphylatoxin C5aC5AR1 protein, human

Autor:innen und Institutionen

  • InflaRx GmbH, Jena, Germany.
  • InflaRx Pharmaceuticals, Inc., Ann Arbor, MI, USA.

Förderung

  • InflaRx

Zitieren

APA

Grippo, J. F., Pfaff, A., Xu, Z., Otto, I., Thielert, C., Imre, M., Liu, R., Phuapradit, W., Pei, Y., Chen, C., Habel, M., Guo, R., & Chong, C. (2026). A First‐In‐Human, Randomized, Placebo‐Controlled Single and Multiple Ascending Dose Study of Izicopan (INF904), A Second‐Generation Oral Small Molecule C5a Receptor Inhibitor, in Healthy Participants. Clinical Pharmacology in Drug Development, 15(11). https://doi.org/10.1002/cpdd.70123

Vancouver

Grippo JF, Pfaff A, Xu Z, Otto I, Thielert C, Imre M, et al. A First‐In‐Human, Randomized, Placebo‐Controlled Single and Multiple Ascending Dose Study of Izicopan (INF904), A Second‐Generation Oral Small Molecule C5a Receptor Inhibitor, in Healthy Participants. Clinical Pharmacology in Drug Development. 2026;15(11). doi:10.1002/cpdd.70123

BibTeX
@article{Grippo2026,
  author = {Grippo, Joseph F and Pfaff, Anja and Xu, Zhongli and Otto, Isabell and Thielert, Claus and Imre, Mihaly and Liu, Rui and Phuapradit, Wantanee and Pei, Yazhong and Chen, Cuie and Habel, Maria and Guo, Renfeng and Chong, Camilla},
  title = {A First‐In‐Human, Randomized, Placebo‐Controlled Single and Multiple Ascending Dose Study of Izicopan (INF904), A Second‐Generation Oral Small Molecule C5a Receptor Inhibitor, in Healthy Participants},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/cpdd.70123}
}
Kostenlos starten →